Recombinant antibodies and recombinant proteins: Prolonged-action drugs
- Authors: Gabibov A.G.1
-
Affiliations:
- Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry
- Issue: Vol 86, No 3 (2016)
- Pages: 169-173
- Section: Scientific Session of the General Meeting of the Russian Academy of Sciences
- URL: https://journals.rcsi.science/1019-3316/article/view/178692
- DOI: https://doi.org/10.1134/S1019331616030114
- ID: 178692
Cite item
Abstract
An intensively developing trend in modern biotechnology is the production of recombinant antibodies and proteins. Recombinant antibodies have immunogenic properties and can stay in the blood for a long time; neutralize pathogens, toxins, and viruses; and destroy tumor cells. Recombinant proteins are widely used to cure, prevent, and diagnose diseases. A topical trend in modern medical biotechnology is the creation of prolonged-action drugs based on proteins obtained by genetic engineering methods. The issue of improving the specificity and selectivity of preparations based on enzymes and antibodies awaits solution. All this can be implemented using the approaches of modern combinatorial chemistry and biology, as well as quantum-mechanical calculations.
About the authors
A. G. Gabibov
Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry
Author for correspondence.
Email: gabibov@gmail.com
Russian Federation, Moscow